可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Naghavi M, Libby P, Falk E,et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I [J]. Circulation,2003,108 (14): 1664 - 1672.
[2] Falk E, Shah PK,Fuster V. Coronary plaque disruption[J]. Circulation ,1995,92 (3):657-671.
[3] 许俊堂,胡大一.对急性冠脉综合征分型的看法[J].中华心血管病杂志,2001,29(9):566-568.
[4] Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay[J].Proc Natl Acad Sci U S A,1962,48 (1):1014-22.
[5] Dollery CM, McEwan JR,Henney AM. Matrix metalloproteases and cardiovascular disease[J]. Circ Res, 1995,77 (5):863-868.
[6] Luttun A, Lutgens E, Manderveld A, et al. Loss of matrix metalloproteinase9 or matrix metalloproteinase12 protects apolipoprotein Edeficient mice against atherosclerotic media destruction but differentially affects plaque growth[J].Circulation, 2004,109(11): 1408 - 1414.
[7] Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques[J]. J Clin Invest,1994,94(6): 2493-2503.
[8] Eckart RE, Uyehara CF, Shry EA,et al. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization[J]. J Interv Cardiol,2004,17(1): 27-31.
[9] Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases2 and 9 are elevated in patients with acute coronary syndromes[J]. J Am Coll Cardiol,1998,32(2): 368-372.
[10]Libby P. Inflammation in atherosclerosis[J]. Nature,2002,420(6917): 868-874.